ACIU — AC Immune SA Share Price
Last Trade - 00:00- $474.74m
- $240.77m
- $3.35m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 23.21 | 20.25 | 7.19 | 111.03 | 15.43 | 40.39 | 70.47 | -16.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Directors
- Douglas Williams (62)
- Andrea Pfeifer CEO (63)
- Martin Velasco NVC (65)
- Joerg Hornstein (42)
- Piergiorgio Donati (49)
- Jean-Fabien Monin CAD (49)
- Marie Kosco-Vilbois (62)
- Johannes Streffer
- Peter Bollmann (66)
- Thomas Graney (55)
- Werner Lanthaler (52)
- Roy Twyman (63)
- Friedrich von Bohlen und Halbach (57)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- February 13th, 2003
- Public Since
- January 19th, 2010
- No. of Shareholders
- 229
- No. of Employees
- 149
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 72,701,715
- Address
- EPFL Innovation Park, Building B, LAUSANNE, 1015
- Web
- https://www.acimmune.com/
- Phone
- +41 213459121
- Contact
- Andrea Pfeifer
- Auditors
- Ernst & Young AG
Latest News for ACIU
Upcoming events for ACIU
Q3 2021 AC Immune SA Earnings Release
Similar to ACIU
ADAMAS PHARMACEUTICALS ORD
NASDAQ Global Market
ADICET BIO ORD
NASDAQ Global Market
AEROVATE THERAPEUTICS ORD
NASDAQ Global Market
AMICUS THERAPEUTICS ORD
NASDAQ Global Market
ARCTURUS THERAPEUTICS HOLDINGS ORD
NASDAQ Global Market
FAQ
As of Today at 19:54 UTC, shares in AC Immune SA are trading at $6.53. This share price information is delayed by 15 minutes.
Shares in AC Immune SA last closed at $6.53 and the price had moved by -7.9% over the past 365 days. In terms of relative price strength the AC Immune SA share price has underperformed the S&P500 Index by -30.12% over the past year.
The overall consensus recommendation for AC Immune SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
AC Immune SA does not currently pay a dividend.
AC Immune SA does not currently pay a dividend.
AC Immune SA does not currently pay a dividend.
To buy shares in AC Immune SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.53, shares in AC Immune SA had a market capitalisation of $474.74m.
Here are the trading details for AC Immune SA:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ACIU
Based on an overall assessment of its quality, value and momentum AC Immune SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AC Immune SA is $15.04. That is 130.28% above the last closing price of $6.53.
Analysts covering AC Immune SA currently have a consensus Earnings Per Share (EPS) forecast of -$0.48 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AC Immune SA. Over the past six months, its share price has underperformed the S&P500 Index by -27.82%.
As of the last closing price of $6.53, shares in AC Immune SA were trading -2.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for AC Immune SA.
AC Immune SA's management team is headed by:
- Douglas Williams -
- Andrea Pfeifer - CEO
- Martin Velasco - NVC
- Joerg Hornstein -
- Piergiorgio Donati -
- Jean-Fabien Monin - CAD
- Marie Kosco-Vilbois -
- Johannes Streffer -
- Peter Bollmann -
- Thomas Graney -
- Werner Lanthaler -
- Roy Twyman -
- Friedrich von Bohlen und Halbach -
We do not have data on AC Immune SA's shareholders